Stemline Therapeutics, Inc. (STML) financial statements (2021 and earlier)

Company profile

Business Address 750 LEXINGTON AVENUE
NEW YORK, NY 10022
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1521641751041246079
Cash and cash equivalents2914271724912
Short-term investments122151147871005167
Receivables121517156  
Inventory, net of allowances, customer advances and progress billings11341  
Inventory11341  
Prepaid expense0001100
Deposits current assets1100000
Other undisclosed current assets4422232
Total current assets:1691851971261346381
Noncurrent Assets
Property, plant and equipment0000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets11112  
Total noncurrent assets:2222200
TOTAL ASSETS:1711871981281366381
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:22222126252117
Accrued liabilities1011111
Employee-related liabilities2644362
Other undisclosed accounts payable and accrued liabilities19161620211514
Other liabilities0000000
Other undisclosed current liabilities11111  
Total current liabilities:23232227262117
Noncurrent Liabilities
Liabilities, other than long-term debt0000000
Other liabilities0000000
Other undisclosed noncurrent liabilities00011  
Total noncurrent liabilities:0001100
Total liabilities:23232327272117
Stockholders' equity
Stockholders' equity attributable to parent1481641751011094264
Common stock0000000
Additional paid in capital534529524434425331326
Accumulated other comprehensive income (loss)10(0)0(0)(0)(0)
Accumulated deficit(387)(366)(348)(333)(316)(289)(262)
Total stockholders' equity:1481641751011094264
TOTAL LIABILITIES AND EQUITY:1711871981281366381

Income statement (P&L) ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Revenues9   5  
Cost of revenue
(Cost of Goods and Services Sold)
(1)(3)(1)(1)(0)  
Gross profit:8(3)(1)(1)5  
Operating expenses(30)(27)(28)(30)(33)(27)(21)
Other undisclosed operating income 1213130  
Operating loss:(22)(18)(15)(17)(28)(27)(21)
Nonoperating income1111100
Investment income, nonoperating1111100
Interest and debt expense(0)    (0)(0)
Other undisclosed loss from continuing operations before equity method investments, income taxes (0)     
Loss from continuing operations before equity method investments, income taxes:(21)(18)(15)(17)(27)(27)(21)
Other undisclosed income from continuing operations before income taxes 00    
Loss from continuing operations before income taxes:(21)(18)(15)(17)(27)(27)(21)
Income tax expense (benefit)(0)0(0)00  
Other undisclosed income from continuing operations     16 
Loss before gain (loss) on sale of properties:(21)(18)(15)(17)(27)(11)(21)
Other undisclosed net loss (0)   (16) 
Net loss available to common stockholders, diluted:(21)(18)(15)(17)(27)(27)(21)

Comprehensive Income ($ in millions)

3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Net loss:(21)(18)(15)(17)(27)(27)(21)
Other comprehensive income (loss)1 (0)00 0
Other undisclosed comprehensive loss (0)   (0) 
Comprehensive loss:(21)(18)(15)(17)(27)(27)(21)
Other undisclosed comprehensive income, net of tax, attributable to parent 0   0 
Comprehensive loss, net of tax, attributable to parent:(21)(18)(15)(17)(27)(27)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: